A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: DRUG: Tislelizumab|DRUG: capecitabine
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University